RPE65 and Leber congenital amaurosis: Ideal results from the first ophthalmic randomized controlled trial in gene therapy prompt the approval of Luxturna, an AAV2-based medication for LCA associated with retinal pigment epithelial 65 (RPE65), by the Food and Drug Administration (FDA) in 2017 [29].